

APR 04 2007  
I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 925683019 US. The date shown below in an envelope addressed to: MS Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 4, 2007

Signature:

*Lenay Rogers*  
(Lenay Rogers)

Patent  
Docket No. 532212000624

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Thomas L. CANTOR et al.

Serial No.: 10/760,091

Filing Date: January 16, 2004

For: METHODS FOR DIFFERENTIATING  
AND MONITORING PARATHYROID  
AND BONE STATUS RELATED  
DISEASES

Examiner: C. Cheu

Group Art Unit: 1641

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of document numbers 54-100 are submitted herewith. However, copies of the remaining documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related applications: Serial Number 09/344,639, filed June 26, 1999, now United States Patent Number 6,743,590, and Serial Number 09/231,422, filed January 14, 1999, now United States Patent Number 6,689,566, which also has Reexamination Control Numbers 90/007,685 and 90/007,732, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609.02 (A)(2). The Examiner is requested to consider and make these documents of record in the application.

sd-355959

04/09/2007 EHAILE1 00000014 031952 10760091  
01 FC:1806 180.00 DA

Document numbers 10 and 59 are from *Scantibodies Laboratory, Inc. v. Immutopics, Inc.*, currently pending in the United States District Court for the Central District of California, Case No. CV04-8871 GPS (MANx). Scantibodies Laboratory, Inc. is the owner of the present application. Document number 59 is a docket report from this litigation. Document number 11 was submitted by the third party requestor in the reexamination of United States Patent Number 6,689,566, and includes a copy of document number 10. The present application is a Continuation of United States Patent No. 6,743,590, which is a Continuation-in-Part of United States Patent No. 6,689,566.

Document numbers 12-15 are from the reexamination proceeding of United States Patent No. 6,030,790, assigned control No. 90/007,412. Document number 16 is from *Nichols Institute Diagnostics, Inc. v. Scantibodies Clinical Laboratory Inc. and Scantibodies Laboratory, Inc.*, U.S.D.C. for the Southern District of California, Case No. 02 CV 0046 B (LAB), appealed at the United States Court of Appeals for the Federal Circuit, Case No. 06-1443.

Document number 17 is a Non-Final Office Action from the Applicants' related application Serial No. 10/641,780, which is also a Continuation of United States Patent No. 6,743,590, which is a Continuation-in-Part of United States Patent No. 6,689,566. Document number 53 is the response to that Office Action, and document number 62 is a Supplemental response. Document numbers 18 and 28 are from the present application, Serial No. 10/760,091, which is a Continuation of United States Patent No. 6,743,590, which is a Continuation-in-Part of United States Patent No. 6,689,566. Document numbers 18 and 28 are submitted herewith to be consistent with other disclosures in the patent family. Document numbers 1 and 2 were cited by the examiner in the Non-Final Office Action (document number 28) from the present application.

Document numbers 19-25 are from the prosecution history of the Applicants' related EP application No. 00 902 406.8-2404 (EP 1 151 307 A1 and EP 1 151 307 A4). Document number 26 is a Non-Final Office Action from the Applicants' related application, Serial No. 10/617,489, which is a Continuation-in-Part of United States Patent No. 6,743,590, which is a Continuation-in-Part of United States Patent No. 6,689,566. Document number 27 was cited by the examiner in the Non-

Final Office Action from 10/617,489 (document number 26). Document numbers 30, 31, and 52 are also from Serial No. 10/617,489.

Document number 29 is from *Nichols Institute Diagnostics, Inc. v. Scantibodies Clinical Laboratory Inc. and Scantibodies Laboratory, Inc.*, U.S.D.C. for the Southern District of California, Case No. 02 CV 0046 B (LAB), appealed at the United States Court of Appeals for the Federal Circuit, Case No. 06-1087.

Document numbers 32 and 61 are from the Applicants' related application, Serial No. 10/945,608. Document numbers 48-51 are from litigation in Japan involving the Applicants. Document numbers 54-58 (copies submitted herewith) are from the Reexamination of United States Patent Number 6,689,566, having Control Numbers 90/007,685 and 90/007,732. The present application is a Continuation of United States Patent No. 6,743,590, which is a Continuation-in-Part of United States Patent No. 6,689,566.

Document number 60 is the decision from the European Patent Office revoking European Patent No. 0 783 522. Applicants initiated the opposition against EP 0 783 522, and have previously disclosed documents from this opposition in the present application.

Document numbers 66-70 on the attached Form PTO/SB/08a/b are from the prosecution history of application number 09/898,398, published as US 2003/0082179. Applicants filed the present application to provoke interference with application number 09/898,398. Document number 71 is from the prosecution of application number 10/921,368, published as US 2005/0003493, which claims the benefit of 09/898,398. Document number 72 is from application number 11/146,598, published as 2006/0024772, which also claims the benefit of 09/898,398. Document numbers 73 and 74 are from application number 11/437,428, published as US 2006/0286107, which also claims the benefit of 09/898,398.

Document numbers 75-86 on the attached Form PTO/SB/08a/b are from the prosecution history of application number 09/730,174, published as US 2002/0110871 and issued as US patent number 6,838,264. Applicants filed related application 10/641,780 to provoke interference with application number 09/730,174. Document numbers 87-93 are from application number

10/954,695, published as US 2005/0260191, which claims the benefit of 09/730,174. Document numbers 94 and 95 are from application number 10/998,927, published as US 2005/0095236, which also claims the benefit of 09/730,174.

Document numbers 96-100 on the attached Form PTO/SB/08a/b are from the prosecution history of application number 10/168,185, published as US 2003/0175802. Applicants filed related application number 10/945,608 to provoke interference with 10/168,185.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_\_ is enclosed.
  - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_\_ is enclosed.

☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532212000624.

Dated: April 4, 2007

Respectfully submitted,

By   
Peng Chen  
Registration No.: 43,543  
MORRISON & FOERSTER LLP  
12531 High Bluff Drive, Suite 100  
San Diego, California 92130-2040  
(858) 720-5117



ALTERNATIVE TO PTO/SB/08a/b (07-05)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/760,091
				Filing Date	January 16, 2004
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	1	of	4	Attorney Docket Number	532212000624

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1.	US-4,824,777	04/1989	Chang et al.	
	2.	US-5,545,553	08/1996	Gotschlich	
	3.	US-2003/0082179	05/2003	Hutchison	
	4.	US-2003/0175802	09/2003	Armbruster et al.	
	5.	US-2005/0003493	01/2005	Hutchison	
	6.	US-2005/0095236	05/2005	Zahradnik et al.	
	7.	US-2005/0260191	11/2005	Zahradnik et al.	
	8.	US-2006/0024772	02/2006	Hutchison	
	9.	US-2006/0286107	12/2006	Hutchison	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	10.	Joint Notice of Status of Reexamination of Patent-In-Suit, filed September 29, 2006 in Scantibodies v. Immutopics, USDC for the Central District of California, Case No. CV 04-8871 GPS (MANx)	
	11.	Notice of Litigation Activity, submitted by the third party requestor, October 6, 2006	
	12.	Ex Parte Reexamination Advisory Action, Control No. 90/007,412, mailed on September 19, 2006	
	13.	Miscellaneous Communication – Notice of Concurrent Proceeding, Control No. 90/007,412, filed September 22, 2006	
	14.	Ex Parte Reexamination Interview Summary, Control No. 90/007,412, mailed on October 10, 2006	
	15.	Notice of Appeal From the Examiner to the Board of Patent Appeals and Interferences, Control No. 90/007,412, filed October 10, 2006	
	16.	Order Granting Stay, filed October 12, 2006, US Court of Appeals for the Federal Circuit, Case No. 2006-1443	
	17.	Non-Final Office Action, from 10/641,780, mailed on October 5, 2006	
	18.	Statement of Substance of Interview, from 10/760,091, filed on October 17, 2006	
	19.	Result of Consultation, from EP Application No. 00 902 406.8 – 2404, dated December 19,	

Examiner Signature	Date Considered
--------------------	-----------------

sd-355937

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/760,091
				Filing Date	January 16, 2004
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	2	of	4	Attorney Docket Number	532212000624

		2005	
	20.	Communication Under Rule 51(4) EPC, from EP Application No. 00 902 406.8 – 2404, dated December 19, 2005	
	21.	Request for correction After IGRA, from EP Application No. 00 902 406.8 – 2404, dated April 27, 2006	
	22.	Documents For Grant, from EP Application No. 00 902 406.8 – 2404, dated May 24, 2006	
	23.	Brief Communication, from EP Application No. 00 902 406.8 – 2404, dated June 12, 2006	
	24.	Receipt of Third Party Observations, from EP Application No. 00 902 406.8 – 2404, dated July 6, 2006 (and English Translation)	
	25.	Communication Pursuant to Article 115(2) EPC, from EP Application No. 00 902 406.8 – 2404, dated July 18, 2006	
	26.	Non-Final Office Action, from 10/617,489, mailed on October 23, 2006	
	27.	RUCINSKI et al., Calcif. Tissue Int. (1995) 56:83-87	
	28.	Non-Final Office Action, from 10/760,091, mailed on October 23, 2006	
	29.	Order Denying Petition for Panel Rehearing and Petition for Rehearing En Banc, United States Court of Appeals for the Federal Circuit, Nichols Institute Diagnostics, Inc. v. Scantibodies Clinical Laboratory, Inc., and Scantibodies Laboratory, Inc., Case No. 06-1087, order issued on November 20, 2006	
	30.	Supplemental Amendment from application serial number 10/617,489, filed November 28, 2006	
	31.	Terminal Disclaimer from application serial number 10/617,489, filed November 28, 2006	
	32.	Non-Final Office Action from application serial number 10/945,608, mailed on November 15, 2006	
	33.	BORN et al., Endocrinology (1988) 123(4):1848-1853	
	34.	BORN et al., Mol. Endocrinol. (1987) 1:5-14	
	35.	BRINGHURST et al., Am. J. Physiol. (1988) 255(6 Pt 1):E886-93	
	36.	BRINGHURST et al., Endocrinology (1981) 108:103-108	
	37.	GARDELLA et al., Journal of Biological Chemistry (1991) 266:13141-13146	
	38.	GOLTZMANN et al., Journal of Biological Chemistry (1975) 250:3199-3203	
	39.	HORIUCHI et al., Am. J. Physiol. (1983) 244(6):E589-95	
	40.	KEUTMANN et al., Endocrinology (1985) 117(3):1230-1234	
	41.	NEER et al., J. Clin. Endocrinol. Metab. (1977) 44(2):420-423	
	42.	REEVE et al., Br. Med. J. (1980) 280:1340-1344	
	43.	ROSENBLATT et al., Biochemistry (1981) 20(25):7246-7250	
	44.	ROSENBLATT et al., Endocrinology (1978) 103(3):978-984	
	45.	SEGRE et al., Endocrinology (1985) 116(3):1024-1029	
	46.	SHIGENO et al., Journal of Biological Chemistry (1988) 263:3864-3871	
	47.	TREGGEAR et al., Endocr. Res. Commun. (1975) 2(8):561-570	
	48.	Case concerning petition for revocation of court ruling No. 10406, 2006, Plaintiff's Brief, November 9, 2006 (Japanese litigation document and English translation, requesting withdrawal of the Japanese Patent Office's invalidation of JP Patent No. 3457004)	x
	49.	Written Answer, November 9, 2006 (Japanese litigation document and English translation, requesting withdrawal of the Japanese Patent Office's invalidation of JP Patent No. 3457004)	x
	50.	Description of Evidence, November 9, 2006 (Japanese litigation document and English translation, requesting withdrawal of the Japanese Patent Office's invalidation of JP Patent No. 3457004)	x
	51.	Brief (The first), November 14, 2006 (Japanese litigation document and English translation,	x

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

sd- 355937

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/760,091
				Filing Date	January 16, 2004
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	3	of	4	Attorney Docket Number	532212000624

		requesting withdrawal of the Japanese Patent Office's invalidation of JP Patent No. 3457004)	
	52.	Notice of Allowance from application serial no. 10/617,489, mailed on January 4, 2007	
	53.	Amendment in Response to Non-Final Office Action, from application serial no. 10/641,780, filed January 5, 2007	
	54.	Final Office Action, from the Reexamination of U.S. Patent No. 6,689,566, Control Numbers 90/007,685 and 90/007,732, mailed on September 21, 2006	
	55.	Response to Final Office Action from the Reexamination of U.S. Patent No. 6,689,566, Control Numbers 90/007,685 and 90/007,732, filed on November 10, 2006	
	56.	Supplemental Response to Final Office Action, from the Reexamination of United States Patent Number 6,689,566, having Control Numbers 90/007,685 and 90/007,732, filed November 20, 2006	
	57.	Second Supplemental Response to Final Office Action from the Reexamination of United States Patent Number 6,689,566, having Control Numbers 90/007,685 and 90/007,732, filed December 1, 2006	
	58.	Notice of Intent to Issue Ex Parte Reexamination Certificate, from the Reexamination of US Patent No. 6,689,566, Control No.'s 90/007,685 and 90/007,732, mailed January 8, 2007	
	59.	Court Docket From PACER for Scantibodies Laboratory, Inc. v. Immutopics, Inc., currently pending at the United States District Court, Central District of California (Western Division), Case No. 2:04-cv-08871-GPS-MAN, docket accessed January 29, 2007	
	60.	Decision of the European Patent Office regarding revocation of European Patent No. 0 783 522, dated January 10, 2007	
	61.	Amendment in Response to Non-Final Office Action, from 10/945,608, filed on February 15, 2007	
	62.	Supplemental Amendment, from 10/641,780, filed on March 27, 2007	
	63.	GRONWALD et al., Biol. Chem. (1996) 377:175-186	
	64.	FISKIN et al., The Journal of Biological Chemistry (1977) 252:8261-8268	
	65.	PELLEGRINI et al., The Journal of Biological Chemistry (1998) 273:10420-10427	
	66.	Non-Final Office Action, from 09/898,398, mailed on November 12, 2003	
	67.	Amendment in Response to November 12, 2003 Office Action, from 09/898,398, filed on February 12, 2004	
	68.	Final Office Action, from 09/898,398, mailed on April 28, 2004	
	69.	Amendment in Response to April 28, 2004 Office Action, from 09/898,398, filed on June 28, 2004	
	70.	Notice of Allowance, from 09/898,398, mailed on July 19, 2004	
	71.	Non-Final Office Action, from 10/921,368, mailed on December 13, 2004	
	72.	Non-Final Office Action, from 11/146,598, mailed on December 19, 2005	
	73.	Non-Final Office Action, from 11/437,428, mailed on October 16, 2006	
	74.	Amendment and Reply Under 37 CFR 1.111. from 11/437,428, filed on March 16, 2007	
	75.	Preliminary Amendment, from 09/730,174, filed on January 9, 2002	
	76.	Restriction Requirement, from 09/730,174, mailed on July 2, 2002	
	77.	Response to Restriction Requirement, from 09/730,174, filed on July 19, 2002	
	78.	Non-Final Office Action, from 09/730,174, mailed on October 1, 2002	
	79.	Amendment, from 09/730,174, filed on December 19, 2002	
	80.	Final Office Action, from 09/730,174, mailed on March 24, 2003	
	81.	Amendment After Final Rejection, from 09/730,174, filed on June 23, 2003	
	82.	Advisory Action, from 09/730,174, mailed on July 15, 2003	
	83.	Amendment & Response to Advisory Action, from 09/730,174, filed on August 14, 2003	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/760,091
				Filing Date	January 16, 2004
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	4	of	4	Attorney Docket Number	532212000624

	84.	Non-Final Office Action, from 09/730,174, mailed on June 15, 2004	
	85.	Amendment & Response to Advisory Action, from 09/730,174, filed on June 30, 2004	
	86.	Notice of Allowance, from 09/730,174, mailed on September 21, 2004	
	87.	Restriction Requirement, from 10/954,695, mailed on September 21, 2005	
	88.	Non-Final Office Action, from 10/954,695, mailed on December 7, 2005	
	89.	Amendment, from 10/954,695, filed on May 30, 2006	
	90.	Final Office Action, from 10/954,695, mailed on August 24, 2006	
	91.	RCE and Preliminary Amendment, from 10/954,695, filed on October 26, 2006	
	92.	Non-Final Office Action, from 10/954,695, mailed on January 3, 2007	
	93.	Response to Office Action, from 10/954,695, filed on March 12, 2007	
	94.	Non-Final Office Action, from 10/998,927, mailed on December 21, 2006	
	95.	Response to Office Action, from 10/998,927, filed on January 2, 2007	
	96.	Preliminary Amendment, from 10/168,185, filed on March 21, 2003	
	97.	Restriction Requirement, from 10/168,185, mailed on January 26, 2006	
	98.	Response to Restriction Requirement, from 10/168,185, filed on July 26, 2006	
	99.	Non-Final Office Action, from 10/168,185, mailed on October 23, 2006	
	100.	Examiner Interview Summary, from 10/168,185, mailed on February 27, 2007	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

sd- 355937



04-06-07

1FW  
\$

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)		Application Number	10/760,091
		Filing Date	January 16, 2004
		First Named Inventor	Thomas L. CANTOR
		Art Unit	1641
		Examiner Name	C. Cheu
Total Number of Pages in This Submission	16	Attorney Docket Number	532212000624

**ENCLOSURES (Check all that apply)**

<input checked="" type="checkbox"/> Fee Transmittal Form (1 page plus duplicate) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (5 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO/SB/08a/b Form (4 pages plus duplicate) References (47) Return Receipt Postcard
<b>Remarks</b>  CUSTOMER NO. 25225		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**


Firm Name	MORRISON & FOERSTER LLP		
Signature			
Printed name	Peng Chen		
Date	April 4, 2007	Reg. No.	43,543

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 915683019 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 4, 2007

Signature:

(Lenay Rogus)



PTO/SB/17 (02-07)

Approved for use through 02/28/2007. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

<b>Effective on 12/08/2004.</b> <b>Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).</b>  <b>FEE TRANSMITTAL</b> <b>For FY 2007</b>		<b>Complete if Known</b>		
		Application Number	10/760,091	
		Filing Date	January 16, 2004	
		First Named Inventor	Thomas L. CANTOR	
		Examiner Name	C. Cheu	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	Art Unit	1641		
TOTAL AMOUNT OF PAYMENT	(\$)	180.00	Attorney Docket No.	532212000624

**METHOD OF PAYMENT (check all that apply)**

<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card	<input type="checkbox"/> Money Order	<input type="checkbox"/> None	<input type="checkbox"/> Other (please identify): _____
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: 03-1952		Deposit Account Name: Morrison & Foerster LLP	
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)				
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee			
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments			

**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

**2. EXCESS CLAIM FEES**

Fee Description	Small Entity	
	Fee (\$)	Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

**Total Claims**      **Extra Claims**      **Fee (\$)**      **Fee Paid (\$)**  
\_\_\_\_\_ - 20 = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_

HP = highest number of total claims paid for, if greater than 20.

**Indep. Claims**      **Extra Claims**      **Fee (\$)**      **Fee Paid (\$)**  
\_\_\_\_\_ - 3 = \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_

HP = highest number of independent claims paid for, if greater than 3.

**3. APPLICATION SIZE FEE**

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<b>Total Sheets</b>	<b>Extra Sheets</b>	<b>Number of each additional 50 or fraction thereof</b>	<b>Fee (\$)</b>	<b>Fee Paid (\$)</b>
_____ - 100 = _____	/50	_____ (round up to a whole number) x _____	= _____	

**4. OTHER FEE(S)**

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement      180.00

<b>SUBMITTED BY</b>			
Signature		Registration No. (Attorney/Agent)	43,543
Name (Print/Type)	Peng Chen	Telephone	(858) 720-5117
		Date	April 4, 2007